{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:43:21Z","timestamp":1792521801008,"version":"4.5.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012713","name":"Leon Lowenstein Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Alzheimer\u2019s disease (AD) and Lewy body disease (LBD) are the two most common neurodegenerative dementias and can occur in combination (AD+LBD). Due to overlapping biomarkers and symptoms, clinical differentiation of these subtypes could be difficult. However, it is unclear how the magnitude of diagnostic uncertainty varies across dementia spectra and demographic variables. We aimed to compare clinical diagnosis and post-mortem autopsy-confirmed pathological results to assess the clinical subtype diagnosis quality across these factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied data of 1,920 participants recorded by the National Alzheimer\u2019s Coordinating Center from 2005 to 2019. Selection criteria included autopsy-based neuropathological assessments for AD and LBD, and the initial visit with Clinical Dementia Rating (CDR) stage of normal, mild cognitive impairment, or mild dementia. Longitudinally, we analyzed the first visit at each subsequent CDR stage. This analysis included positive predictive values, specificity, sensitivity and false negative rates of clinical diagnosis, as well as disparities by sex, race, age, and education. If autopsy-confirmed AD and\/or LBD was missed in the clinic, the alternative clinical diagnosis was analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>In our findings, clinical diagnosis of AD+LBD had poor sensitivities. Over 61% of participants with autopsy-confirmed AD+LBD were diagnosed clinically as AD. Clinical diagnosis of AD had a low sensitivity at the early dementia stage and low specificities at all stages. Among participants diagnosed as AD in the clinic, over 32% had concurrent LBD neuropathology at autopsy. Among participants diagnosed as LBD, 32% to 54% revealed concurrent autopsy-confirmed AD pathology. When three subtypes were missed by clinicians, \u201cNo cognitive impairment\u201d and \u201cprimary progressive aphasia or behavioral variant frontotemporal dementia\u201d were the leading primary etiologic clinical diagnoses. With increasing dementia stages, the clinical diagnosis accuracy of black participants became significantly worse than other races, and diagnosis quality significantly improved for males but not females.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These findings demonstrate that clinical diagnosis of AD, LBD, and AD+LBD are inaccurate and suffer from significant disparities on race and sex. They provide important implications for clinical management, anticipatory guidance, trial enrollment and applicability of potential therapies for AD, and promote research into better biomarker-based assessment of LBD pathology.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnagi.2023.1149036","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T05:30:16Z","timestamp":1679376616000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["On gaps of clinical diagnosis of dementia subtypes: A study of Alzheimer\u2019s disease and Lewy body disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Hui","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun V.","family":"Masurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Razavian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of aducanumab for alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility.","volume":"325","author":"Alexander","year":"2021","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/alz.12328","article-title":"Alzheimer\u2019s disease facts and figures.","volume":"17","year":"2021","journal-title":"Alzheimers Dement."},{"key":"B3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.14283\/jpad.2022.85","article-title":"Blood biomarkers from research use to clinical practice: what must be done? a report from the EU\/US CTAD task force.","volume":"9","author":"Angioni","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer disease centers, 2005-2010.","volume":"71","author":"Beach","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1212\/WNL.0000000000200878","article-title":"\u03b1-Synuclein seed amplification assays for diagnosing synucleinopathies: the way forward.","volume":"99","author":"Bellomo","year":"2022","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1126\/science.aal0759","article-title":"Another Alzheimer\u2019s drug flops in pivotal clinical trial.","volume":"293","author":"Carroll","year":"2017","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12189","article-title":"Clinico-pathological comparison of patients with autopsy-confirmed Alzheimer\u2019s disease, dementia with Lewy bodies, and mixed pathology.","volume":"13","author":"Chatterjee","year":"2021","journal-title":"Alzheimers Dement."},{"key":"B8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/WAD.0b013e318211c6c9","article-title":"Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease.","volume":"25","author":"Chin","year":"2011","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1182","DOI":"10.1212\/WNL.0000000000006212","article-title":"APOE \u03b54 is associated with severity of lewy body pathology independent of Alzheimer pathology.","volume":"91","author":"Dickson","year":"2018","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease.","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/PL00014176","article-title":"The Lewy body variant of Alzheimer\u2019s disease: clinical, pathophysiological and conceptual issues.","volume":"249","author":"F\u00f6rstl","year":"1999","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.trci.2019.11.008","article-title":"Racial disparities and temporal trends in dementia misdiagnosis risk in the United States.","volume":"5","author":"Gianattasio","year":"2019","journal-title":"Alzheimers Dement."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/alz.12511","article-title":"Alzheimer\u2019s disease biomarkers in black and non-Hispanic white cohorts: a contextualized review of the evidence.","volume":"18","author":"Gleason","year":"2022","journal-title":"Alzheimers Dement."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00703-5","article-title":"Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.","volume":"12","author":"Goldman","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-7091-6846-2_7","article-title":"The Lewy body variant of Alzheimer disease.","volume":"51","author":"Hansen","year":"1997","journal-title":"J. Neural Transm. Suppl."},{"key":"B16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease.","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0609-7","article-title":"Clinical trials of new drugs for Alzheimer disease.","volume":"27","author":"Huang","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/2047-9158-2-4","article-title":"Can we clinically diagnose dementia with Lewy bodies yet?","volume":"2","author":"Huang","year":"2013","journal-title":"Transl. Neurodegener."},{"key":"B19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1176\/appi.ps.54.1.92","article-title":"Racial differences in the diagnosis of dementia and in its effects on the use and costs of health care services.","volume":"54","author":"Husaini","year":"2003","journal-title":"Psychiatr. Serv."},{"key":"B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National institute on aging-Alzheimer\u2019s association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease.","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement."},{"key":"B21","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1046\/j.1440-1789.1999.00264.x","article-title":"Clinicopathological multiplicity of dementia with Lewy bodies.","volume":"19","author":"Iseki","year":"1999","journal-title":"Neuropathology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3233\/JAD-220297","article-title":"Neuropathological and clinical correlates of lewy body disease survival by race and ethnicity in the national Alzheimer\u2019s coordinating center.","volume":"89","author":"Kurasz","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3233\/JAD-2011-102139","article-title":"Amyloid clearance as a treatment target against Alzheimer\u2019s disease.","volume":"24","author":"Kurz","year":"2011","journal-title":"J. Alzheimers. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/13543784.2019.1681398","article-title":"Clinical drug development for dementia with Lewy bodies: past and present.","volume":"28","author":"Lee","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/alz.043183","article-title":"Dementia diagnosis disparities by race and ethnicity.","volume":"16","author":"Lin","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0063-8","article-title":"History and progress of hypotheses and clinical trials for Alzheimer\u2019s disease.","volume":"4","author":"Liu","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.clinthera.2021.05.005","article-title":"Effect of social determinants of health on cognition and risk of Alzheimer disease and related dementias.","volume":"43","author":"Majoka","year":"2021","journal-title":"Clin. Ther."},{"key":"B28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cger.2003.10.004","article-title":"Cultural influences on dementia recognition and management.","volume":"20","author":"Manly","year":"2004","journal-title":"Clin. Geriatr. Med."},{"key":"B29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium.","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium.","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on aging-Alzheimer\u2019s association workgroups on diagnostic.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","article-title":"The clinical dementia rating (CDR): current version and scoring rules.","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/archneur.1989.00520420071025","article-title":"Clinical and pathological aspects of parkinsonism in Alzheimer\u2019s disease. a role for extranigral factors?","volume":"46","author":"Morris","year":"1989","journal-title":"Arch. Neurol."},{"key":"B34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S1474-4422(17)30074-1","article-title":"The prognosis of dementia with Lewy bodies.","volume":"16","author":"Mueller","year":"2017","journal-title":"Lancet Neurol."},{"key":"B35","year":"2021","journal-title":"NIA-Funded Active Alzheimer\u2019s and Related Dementias Clinical Trials and Studies."},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease.","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers. Res. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1532-5415.2011.03766.x","article-title":"Diagnostic validity of age and education corrections for the mini-mental state examination in older African Americans.","volume":"60","author":"Pedraza","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"key":"B38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer\u2019s disease.","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00702-018-01967-w","article-title":"Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the brains for dementia research (BDR) cohort.","volume":"126","author":"Selvackadunco","year":"2019","journal-title":"J. Neural Transm."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3233\/JAD-180789","article-title":"Clinical-neuropathological correlations of Alzheimer\u2019s disease and related dementias in latino volunteers.","volume":"66","author":"Soria","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-12-804766-8.00013-3","article-title":"Chapter 13 - Alzheimer\u2019s disease","author":"Soria Lopez","year":"2019","journal-title":"Handbook of Clinical Neurology"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2020.44","article-title":"Clinical diagnosis of Lewy body dementia.","volume":"6","author":"Surendranathan","year":"2020","journal-title":"BJPsych Open"},{"key":"B43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","article-title":"Lewy body dementias.","volume":"386","author":"Walker","year":"2015","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","article-title":"Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.","volume":"86","author":"Wang","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000285145","article-title":"Light therapy for depression: present status, problems, and perspectives.","volume":"19","author":"Wirz-Justice","year":"1986","journal-title":"Psychopathology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3928\/00989134-20060401-08","article-title":"Assessing cognitive ability in research: use of MMSE with minority populations and elderly adults with low education levels.","volume":"32","author":"Wood","year":"2006","journal-title":"J. Gerontol. Nurs."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2023.1149036\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T05:30:24Z","timestamp":1679376624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2023.1149036\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":47,"alternative-id":["10.3389\/fnagi.2023.1149036"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2023.1149036","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"article-number":"1149036"}}